Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors

High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatin...

Full description

Saved in:
Bibliographic Details
Published in:Contrast media and molecular imaging 2018-01, Vol.2018 (2018), p.1-11
Main Authors: Deyev, Sergey, Tolmachev, Vladimir, Proshkina, Galina, Shulga, Alexey, Orlova, Anna, Mitran, Bogdan, Altai, Mohamed, Bragina, Olga, Vorobyeva, Anzhelika, Chernov, Vladimir
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c480t-bc23fe4609e1d6926af3b4412934c7dbbc3ff93bc2ce74a3e2fb87ab5d37f9473
cites cdi_FETCH-LOGICAL-c480t-bc23fe4609e1d6926af3b4412934c7dbbc3ff93bc2ce74a3e2fb87ab5d37f9473
container_end_page 11
container_issue 2018
container_start_page 1
container_title Contrast media and molecular imaging
container_volume 2018
creator Deyev, Sergey
Tolmachev, Vladimir
Proshkina, Galina
Shulga, Alexey
Orlova, Anna
Mitran, Bogdan
Altai, Mohamed
Bragina, Olga
Vorobyeva, Anzhelika
Chernov, Vladimir
description High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib). Radionuclide molecular imaging of HER2 expression might permit stratification of patients for HER2-targeting therapies. In this study, we evaluated a new HER2-imaging probe based on the designed ankyrin repeat protein (DARPin) 9_29. DARPin 9_29 was labeled with iodine-125 by direct radioiodination and with [99mTc]Tc(CO)3 using the C-terminal hexahistidine tag. DARPin 9_29 preserved high specificity and affinity of binding to HER2-expressing cells after labeling. Uptake of [125I]I-DARPin 9_29 and [99mTc]Tc(CO)3-DARPin 9_29 in HER2-positive SKOV-3 xenografts in mice at 6 h after injection was 3.4 ± 0.7 %ID/g and 2.9 ± 0.7 %ID/g, respectively. This was significantly (p
doi_str_mv 10.1155/2018/6930425
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_DiVA_org_uu_359679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2066474594</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-bc23fe4609e1d6926af3b4412934c7dbbc3ff93bc2ce74a3e2fb87ab5d37f9473</originalsourceid><addsrcrecordid>eNqNkcFv0zAYxSMEYmNw44x8RIIwO3bi-oJUdYVN6gSqClfLcT6nRo7d2UkH_wZ_MYlaOnbDF3-yf--9T3pZ9prgD4SU5WWByeyyEhSzonySnY9PZc4o4U9PMxZn2YuUfmDMGBX0eXZWCME54fQ8-70I3U5F1ds9oOVeuWEcg0fBoLVqbLChsR6Q8g3agN566O3Q5StVg4MGXc3XX61HQhYCmRAPEj9oZxtAt8GBHpyK6KZTrfXtZHq9XBdo-XMXIaUpZ1TfKmdbr3yPNkMXYnqZPTPKJXh1vC-yb5-Wm8V1vvry-WYxX-WazXCf17qgBliFBZCmEkWlDK0ZI4WgTPOmrjU1RtAR08CZolCYesZVXTaUG8E4vcjeH3zTPeyGWu6i7VT8JYOy8sp-n8sQWzkMkpai4mLEPx7wke2g0eD7qNwj1eMfb7eyDXtZYTKeKe_t0SCGuwFSLzubNDinPIQhyQJXFeOsFOxhNR1DShHMKYZgObUup9blsfURf_Pvaif4b80j8O4AbK1v1L39TzsYGTDqgSaUlITRP2nbwVA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2066474594</pqid></control><display><type>article</type><title>Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors</title><source>Open Access: PubMed Central</source><creator>Deyev, Sergey ; Tolmachev, Vladimir ; Proshkina, Galina ; Shulga, Alexey ; Orlova, Anna ; Mitran, Bogdan ; Altai, Mohamed ; Bragina, Olga ; Vorobyeva, Anzhelika ; Chernov, Vladimir</creator><contributor>Huang, Ya-Yao</contributor><creatorcontrib>Deyev, Sergey ; Tolmachev, Vladimir ; Proshkina, Galina ; Shulga, Alexey ; Orlova, Anna ; Mitran, Bogdan ; Altai, Mohamed ; Bragina, Olga ; Vorobyeva, Anzhelika ; Chernov, Vladimir ; Huang, Ya-Yao</creatorcontrib><description>High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib). Radionuclide molecular imaging of HER2 expression might permit stratification of patients for HER2-targeting therapies. In this study, we evaluated a new HER2-imaging probe based on the designed ankyrin repeat protein (DARPin) 9_29. DARPin 9_29 was labeled with iodine-125 by direct radioiodination and with [99mTc]Tc(CO)3 using the C-terminal hexahistidine tag. DARPin 9_29 preserved high specificity and affinity of binding to HER2-expressing cells after labeling. Uptake of [125I]I-DARPin 9_29 and [99mTc]Tc(CO)3-DARPin 9_29 in HER2-positive SKOV-3 xenografts in mice at 6 h after injection was 3.4 ± 0.7 %ID/g and 2.9 ± 0.7 %ID/g, respectively. This was significantly (p&lt;0.00005) higher than the uptake of the same probes in HER2-negative Ramos lymphoma xenografts, 0.22 ± 0.09 %ID/g and 0.30 ± 0.05 %ID/g, respectively. Retention of [125I]I-DARPin 9_29 in the lung, liver, spleen, and kidneys was appreciably lower compared with [99mTc]Tc(CO)3-DARPin 9_29, which resulted in significantly (p&lt;0.05) higher tumor-to-organ ratios. The biodistribution data were confirmed by SPECT/CT imaging. In conclusion, radioiodine is a preferable label for DARPin 9_29.</description><identifier>ISSN: 1555-4309</identifier><identifier>ISSN: 1555-4317</identifier><identifier>EISSN: 1555-4317</identifier><identifier>DOI: 10.1155/2018/6930425</identifier><identifier>PMID: 29977173</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><ispartof>Contrast media and molecular imaging, 2018-01, Vol.2018 (2018), p.1-11</ispartof><rights>Copyright © 2018 Anzhelika Vorobyeva et al.</rights><rights>Copyright © 2018 Anzhelika Vorobyeva et al. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-bc23fe4609e1d6926af3b4412934c7dbbc3ff93bc2ce74a3e2fb87ab5d37f9473</citedby><cites>FETCH-LOGICAL-c480t-bc23fe4609e1d6926af3b4412934c7dbbc3ff93bc2ce74a3e2fb87ab5d37f9473</cites><orcidid>0000-0002-4778-3909 ; 0000-0001-6120-2683 ; 0000-0002-6122-1734 ; 0000-0001-7921-3268</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011117/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011117/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29977173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-359679$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>Huang, Ya-Yao</contributor><creatorcontrib>Deyev, Sergey</creatorcontrib><creatorcontrib>Tolmachev, Vladimir</creatorcontrib><creatorcontrib>Proshkina, Galina</creatorcontrib><creatorcontrib>Shulga, Alexey</creatorcontrib><creatorcontrib>Orlova, Anna</creatorcontrib><creatorcontrib>Mitran, Bogdan</creatorcontrib><creatorcontrib>Altai, Mohamed</creatorcontrib><creatorcontrib>Bragina, Olga</creatorcontrib><creatorcontrib>Vorobyeva, Anzhelika</creatorcontrib><creatorcontrib>Chernov, Vladimir</creatorcontrib><title>Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors</title><title>Contrast media and molecular imaging</title><addtitle>Contrast Media Mol Imaging</addtitle><description>High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib). Radionuclide molecular imaging of HER2 expression might permit stratification of patients for HER2-targeting therapies. In this study, we evaluated a new HER2-imaging probe based on the designed ankyrin repeat protein (DARPin) 9_29. DARPin 9_29 was labeled with iodine-125 by direct radioiodination and with [99mTc]Tc(CO)3 using the C-terminal hexahistidine tag. DARPin 9_29 preserved high specificity and affinity of binding to HER2-expressing cells after labeling. Uptake of [125I]I-DARPin 9_29 and [99mTc]Tc(CO)3-DARPin 9_29 in HER2-positive SKOV-3 xenografts in mice at 6 h after injection was 3.4 ± 0.7 %ID/g and 2.9 ± 0.7 %ID/g, respectively. This was significantly (p&lt;0.00005) higher than the uptake of the same probes in HER2-negative Ramos lymphoma xenografts, 0.22 ± 0.09 %ID/g and 0.30 ± 0.05 %ID/g, respectively. Retention of [125I]I-DARPin 9_29 in the lung, liver, spleen, and kidneys was appreciably lower compared with [99mTc]Tc(CO)3-DARPin 9_29, which resulted in significantly (p&lt;0.05) higher tumor-to-organ ratios. The biodistribution data were confirmed by SPECT/CT imaging. In conclusion, radioiodine is a preferable label for DARPin 9_29.</description><issn>1555-4309</issn><issn>1555-4317</issn><issn>1555-4317</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkcFv0zAYxSMEYmNw44x8RIIwO3bi-oJUdYVN6gSqClfLcT6nRo7d2UkH_wZ_MYlaOnbDF3-yf--9T3pZ9prgD4SU5WWByeyyEhSzonySnY9PZc4o4U9PMxZn2YuUfmDMGBX0eXZWCME54fQ8-70I3U5F1ds9oOVeuWEcg0fBoLVqbLChsR6Q8g3agN566O3Q5StVg4MGXc3XX61HQhYCmRAPEj9oZxtAt8GBHpyK6KZTrfXtZHq9XBdo-XMXIaUpZ1TfKmdbr3yPNkMXYnqZPTPKJXh1vC-yb5-Wm8V1vvry-WYxX-WazXCf17qgBliFBZCmEkWlDK0ZI4WgTPOmrjU1RtAR08CZolCYesZVXTaUG8E4vcjeH3zTPeyGWu6i7VT8JYOy8sp-n8sQWzkMkpai4mLEPx7wke2g0eD7qNwj1eMfb7eyDXtZYTKeKe_t0SCGuwFSLzubNDinPIQhyQJXFeOsFOxhNR1DShHMKYZgObUup9blsfURf_Pvaif4b80j8O4AbK1v1L39TzsYGTDqgSaUlITRP2nbwVA</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Deyev, Sergey</creator><creator>Tolmachev, Vladimir</creator><creator>Proshkina, Galina</creator><creator>Shulga, Alexey</creator><creator>Orlova, Anna</creator><creator>Mitran, Bogdan</creator><creator>Altai, Mohamed</creator><creator>Bragina, Olga</creator><creator>Vorobyeva, Anzhelika</creator><creator>Chernov, Vladimir</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0002-4778-3909</orcidid><orcidid>https://orcid.org/0000-0001-6120-2683</orcidid><orcidid>https://orcid.org/0000-0002-6122-1734</orcidid><orcidid>https://orcid.org/0000-0001-7921-3268</orcidid></search><sort><creationdate>20180101</creationdate><title>Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors</title><author>Deyev, Sergey ; Tolmachev, Vladimir ; Proshkina, Galina ; Shulga, Alexey ; Orlova, Anna ; Mitran, Bogdan ; Altai, Mohamed ; Bragina, Olga ; Vorobyeva, Anzhelika ; Chernov, Vladimir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-bc23fe4609e1d6926af3b4412934c7dbbc3ff93bc2ce74a3e2fb87ab5d37f9473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deyev, Sergey</creatorcontrib><creatorcontrib>Tolmachev, Vladimir</creatorcontrib><creatorcontrib>Proshkina, Galina</creatorcontrib><creatorcontrib>Shulga, Alexey</creatorcontrib><creatorcontrib>Orlova, Anna</creatorcontrib><creatorcontrib>Mitran, Bogdan</creatorcontrib><creatorcontrib>Altai, Mohamed</creatorcontrib><creatorcontrib>Bragina, Olga</creatorcontrib><creatorcontrib>Vorobyeva, Anzhelika</creatorcontrib><creatorcontrib>Chernov, Vladimir</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><jtitle>Contrast media and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deyev, Sergey</au><au>Tolmachev, Vladimir</au><au>Proshkina, Galina</au><au>Shulga, Alexey</au><au>Orlova, Anna</au><au>Mitran, Bogdan</au><au>Altai, Mohamed</au><au>Bragina, Olga</au><au>Vorobyeva, Anzhelika</au><au>Chernov, Vladimir</au><au>Huang, Ya-Yao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors</atitle><jtitle>Contrast media and molecular imaging</jtitle><addtitle>Contrast Media Mol Imaging</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>2018</volume><issue>2018</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>1555-4309</issn><issn>1555-4317</issn><eissn>1555-4317</eissn><abstract>High expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib). Radionuclide molecular imaging of HER2 expression might permit stratification of patients for HER2-targeting therapies. In this study, we evaluated a new HER2-imaging probe based on the designed ankyrin repeat protein (DARPin) 9_29. DARPin 9_29 was labeled with iodine-125 by direct radioiodination and with [99mTc]Tc(CO)3 using the C-terminal hexahistidine tag. DARPin 9_29 preserved high specificity and affinity of binding to HER2-expressing cells after labeling. Uptake of [125I]I-DARPin 9_29 and [99mTc]Tc(CO)3-DARPin 9_29 in HER2-positive SKOV-3 xenografts in mice at 6 h after injection was 3.4 ± 0.7 %ID/g and 2.9 ± 0.7 %ID/g, respectively. This was significantly (p&lt;0.00005) higher than the uptake of the same probes in HER2-negative Ramos lymphoma xenografts, 0.22 ± 0.09 %ID/g and 0.30 ± 0.05 %ID/g, respectively. Retention of [125I]I-DARPin 9_29 in the lung, liver, spleen, and kidneys was appreciably lower compared with [99mTc]Tc(CO)3-DARPin 9_29, which resulted in significantly (p&lt;0.05) higher tumor-to-organ ratios. The biodistribution data were confirmed by SPECT/CT imaging. In conclusion, radioiodine is a preferable label for DARPin 9_29.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>29977173</pmid><doi>10.1155/2018/6930425</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-4778-3909</orcidid><orcidid>https://orcid.org/0000-0001-6120-2683</orcidid><orcidid>https://orcid.org/0000-0002-6122-1734</orcidid><orcidid>https://orcid.org/0000-0001-7921-3268</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1555-4309
ispartof Contrast media and molecular imaging, 2018-01, Vol.2018 (2018), p.1-11
issn 1555-4309
1555-4317
1555-4317
language eng
recordid cdi_swepub_primary_oai_DiVA_org_uu_359679
source Open Access: PubMed Central
title Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A34%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20Evaluation%20of%20Radioiodine%20and%20Technetium-Labeled%20DARPin%209_29%20for%20Radionuclide%20Molecular%20Imaging%20of%20HER2%20Expression%20in%20Malignant%20Tumors&rft.jtitle=Contrast%20media%20and%20molecular%20imaging&rft.au=Deyev,%20Sergey&rft.date=2018-01-01&rft.volume=2018&rft.issue=2018&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=1555-4309&rft.eissn=1555-4317&rft_id=info:doi/10.1155/2018/6930425&rft_dat=%3Cproquest_swepu%3E2066474594%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c480t-bc23fe4609e1d6926af3b4412934c7dbbc3ff93bc2ce74a3e2fb87ab5d37f9473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2066474594&rft_id=info:pmid/29977173&rfr_iscdi=true